Condition: Tetanus · Sponsor: Zhuhai Trinomab Pharmaceutical Co., Ltd.
The injury and wound conditions of the enrolled patients will be documented. A follow-up at 90 days post-administration will determine the clinical outcome of tetanus prophylaxis, specifically whether tetanus occurred. The registry will also employ selective safety data collection to record adverse reactions and serious adverse events following Siltartoxatug adminstration.
This description comes directly from the study's public registry record.
Xia Qu, Master · +86 0756 726399 · sammi.qu@trinomab.com
xinyu Liu, Doctor · +86 0756 7263999 · liuxinyu@trinomab.com
Always discuss trial participation with your own doctor first.
| The Second Affiliated Hospital of Shantou University | Shantou, Guangdong, China | Not Yet Recruiting |
| Xiangyun County People's Hospital | Xiangyun, Yunnan, China | Not Yet Recruiting |
| Shaoxing Central Hospital | Shaoxing, Zhejiang, China | Recruiting |
| Zhoushan Putuo District People's Hospital | Zhoushan, Zhejiang, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07107932